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A recent study inMolecular Cell (Tsukahara et al., 2010) identifies cyclic phosphatidic acid (CPA) as a naturally
occurring PPARg antagonist that can be generated from lysophospholipids by signal-dependent activation
of phospholipase D2. This endogenous CPA regulates PPARg functions required for adipogenesis, glucose
homeostasis, and vascular wall biology.The peroxisome proliferator-activated
receptor g (PPARg) is a member of the
nuclear receptor family of ligand-depen-
dent transcription factors that plays essen-
tial roles in adipogenesis and glucose
homeostasis and the molecular target of
the thiazolidinedione (TZD) class of
insulin-sensitizing agents used clinically to
treat type 2 diabetes (Spiegelman, 1998).
PPARg has a large, promiscuous ligand-
binding pocket and can be activated by
a diverse spectrum of phospholipid and
fatty acid metabolites, including select
leukotrienes, prostaglandins, modified
fatty acids, and oxidized phospholipids
(Chou et al., 2007, and references therein).
Despite the abundance of naturally occur-
ring molecules that activate PPARg in
cell-based assays, the identities of the
endogenous ligands of PPARg that are of
actual physiological importance in specific
tissue contexts remain poorly defined.
A recent paper published by Tsukahara
and colleagues in Molecular Cell (Tsuka-
haraetal., 2010)provides thefirstevidence
for an endogenously produced PPARg
antagonist. They report that cyclic phos-
phatidic acid (CPA), a simple lysophospho-
lipidofpoorlycharacterized function,binds
to PPARg with nanomolar affinity and
antagonizes its activation by synthetic or
naturally occurring agonists. Under physi-
ological conditions, PPARg positively
regulates gene expression by binding as
a heterodimer with RXRs to PPAR
response elements in the vicinity of target
genes. Agonists increase PPARg-depen-
dent gene expression by stimulating inter-
actions with coactivators, such as
PGC1a, SRC proteins, and the TRAP220
component of the mediator complex, and
simultaneously reducing interactions withcorepressors, such as NCoR and SMRT
(Figure 1A). This ligand-dependent coacti-
vator/corepressor exchange results in
transcriptional activation of genes involved
in the control of adipogenesis and insulin
action, as well as a diverse range of other
functions that include fluid and electrolyte
homeostasis, immune cell function, and
bonehomeostasis. Incontrast toactivating
ligands, CPA was shown to stabilize the
binding of the corepressor SMRT and to
block TZD-stimulated adipogenesis and
lipid accumulation in RAW macrophages.
CPAhasbeendetected in humanserum
by mass spectroscopy at concentrations
of 10 nM (Shan et al., 2008), but the
mechanisms responsible for its produc-
tion in mammalian cells remain poorly
defined. Tsukahara et al. (2010) provide
evidence that CPA is produced from lyso-
phosphatidylcholine (lyso-PC) dependent
on phospholipase D2 (Figure 1B). Low-
dose insulin and phorbol ester treatment
of cells stimulate PLD2 activity, increase
levels of CPA, and inhibit PPARg activity.
Although the production of CPA by PLD2
represents an unusual reaction product,
and care must be taken to ensure that
CPA is not artifactually produced by acid
extraction (Shan et al., 2008), the authors
show that reduction of PLD2 expression
reduces CPA accumulation and relieves
PPARg inhibition. TZDs have been shown
to reduce carotid neointimal proliferation
in patients with type 2 diabetes (Mazzone
et al., 2006), but direct application of the
TZD rosiglitazone to the corotid artery
wall of rats paradoxically induces neointi-
mal proliferation (Cheng et al., 2009). Tsu-
kahara and colleagues used this model to
show that the proliferative effect of rosigli-
tazone could be blocked by coadministra-Cell Metabolism 12, Stion of CPA, indicating that it can exert
antagonistic effects in vivo.
These observations raise numerous
interesting questions for future investiga-
tion. In particular, it will be important to
evaluate the production of CPA in relation-
ship to that of endogenous agonists in
tissues in which PPARg plays important
regulatory roles. Although there remains
limited knowledge of relevant physio-
logical PPARg activators, a recently identi-
fiedenzymaticpathway leading toproduc-
tion of 15-keto-PGE2 as an endogenous
PPARg agonist in adipocytes and colonic
epithelial cells (Chou et al., 2007; Harmon
et al., 2010) provides an instructive
example for thinking about some of the
possibilities. As illustrated in Figure 1B,
production of CPA requires lyso PC as
asubstrate. This is generatedbyphospho-
lipase A2 (PLA2) acting on phosphatidyl
choline, which simultaneously liberates
a polyunsaturated fatty acid (PUFA) from
the sn-2position of the glycerol backbone.
ThesePUFAs thencanserveassubstrates
for enzymes that generate PPARg
agonists, such as 15-keto-PGE2. PLA2,
PLD2, and enzymes that potentially
generate endogenous PPARg agonists
are all subject to signal-dependent con-
trol. It will be of considerable interest to
determine whether alterations in these
pathways lead to increased CPA produc-
tion and contribute to a defect in PPARg
function that is reversed by TZD therapy.
More generally, how is the production of
agonist and antagonist balanced? By
which intracellular mechanisms do cells
monitor PPARg activity?
In addition to positive regulation of gene
expression, anti-inflammatory activities of
PPARg have been suggested to contributeeptember 8, 2010 ª2010 Elsevier Inc. 207
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Figure 1. Regulation of PPARg Activity by Cyclic Phosphatidic Acid
(A) PPARg positively regulates the expression of genes involved in adipogenesis, glucose homeostasis,
immune cell function, etc., by binding to PPAR response elements as a heterodimer with RXRs. PPARg
agonists, such as thiazolidinediones (TZDs) and 15-keto PGE2, promote interactions with coactivator
proteins that include PGC1a, SRCs, and TRAP220. These factors are components of multiprotein
complexes that modify chromatin components, for example through the histone acetyltransferase
(HAT) activities of CBP/p300 and recruit basal transcriptional machinery, resulting in enhanced gene
expression. Antagonists, such as CPA, instead stabilize interactions with nuclear receptor corepressors,
such as NCoR and SMRT, that act to repress gene transcription. These factors are also components of
multiprotein complexes and contain enzymes, such as histone deacetylases (e.g., HDAC3) that antago-
nize the actions of coactivators.
(B) Shown are metabolic pathways that produce CPA and the recently identified endogenous PPARg
agonist 15-keto PGE2. PLA2, phospholipase A2; PLD2, phospholipase D2; Hpgd, 15-hydroxyprostaglan-
din dehydrogenase. The structure of CPA is illustrated at the bottom.
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Previewsto antidiabetic activities of TZDs, particu-
larly in macrophages (Odegaard et al.,
2007; Hevener et al., 2007). It will therefore
be of interest to evaluate whether CPA is
produced in macrophages and antago-
nizes the ability of PPARg to suppress
inflammatory responses. The potential
roles of CPA in an inflammatory context
are also relevant in light of the recent208 Cell Metabolism 12, September 8, 2010 ªfinding that PPARg is phosphorylated at
serine 273 in adipose tissue by Cdk5 in
response to proinflammatory stimuli (Choi
et al., 2010). Serine 273 phosphorylation
appears to impair the insulin-sensitizing
activities of PPARg disproportionately to
its adipogenicactivities thataredependent
on classical ligand-dependent agonism.
Intriguingly, TZDs and a selective PPARg2010 Elsevier Inc.modulator that is a relatively poor classical
agonist but retains antidiabetic activity
inhibit S273 phosphorylation. This is not
due to inhibition of Cdk5 itself, but rather
appears to result from allosteric effects
on PPARg that alter its ability to serve as
an effective Cdk5 substrate. These obser-
vations therefore raise the questions of
whether CPA might have an opposite
effect (i.e., make PPARg a better substrate
for Cdk5) and/or whether proinflammatory
stimuli that induce Cdk5 activitymight also
lead to increasedCPAproduction.Overall,
these observations point to as-yet-
uncharted aspects of PPARg biology and
the potential to differentially regulate its
diverse activities by structurally distinct
ligands.The identificationofCPAasanatu-
rally occurring PPARg agonist opens up
new avenues of investigation into mecha-
nisms underlying insulin resistance, the
molecular basis of the action of synthetic
PPARg agonists, and approaches to the
development of improved antidiabetic
and anti-inflammatory drugs.REFERENCES
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